PortalPublikationenΔ133p53 is an independent prognostic marker in p53 mutant ad...

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

Standard

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. / Hofstetter, G; Berger, A; Schuster, E; Wolf, A; Hager, G; Vergote, I; Cadron, I; Sehouli, J; Braicu, E I; Mahner, S; Speiser, P; Marth, C; Zeimet, A G; Ulmer, H; Zeillinger, R; Concin, N.

in: BRIT J CANCER, Jahrgang 105, Nr. 10, 08.11.2011, S. 1593-9.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Hofstetter, G, Berger, A, Schuster, E, Wolf, A, Hager, G, Vergote, I, Cadron, I, Sehouli, J, Braicu, EI, Mahner, S, Speiser, P, Marth, C, Zeimet, AG, Ulmer, H, Zeillinger, R & Concin, N 2011, 'Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer', BRIT J CANCER, Jg. 105, Nr. 10, S. 1593-9. https://doi.org/10.1038/bjc.2011.433

APA

Hofstetter, G., Berger, A., Schuster, E., Wolf, A., Hager, G., Vergote, I., Cadron, I., Sehouli, J., Braicu, E. I., Mahner, S., Speiser, P., Marth, C., Zeimet, A. G., Ulmer, H., Zeillinger, R., & Concin, N. (2011). Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. BRIT J CANCER, 105(10), 1593-9. https://doi.org/10.1038/bjc.2011.433

Vancouver

Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I et al. Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer. BRIT J CANCER. 2011 Nov 8;105(10):1593-9. https://doi.org/10.1038/bjc.2011.433

Bibtex

@article{c715c15918564452adefc7ccdf8d20a9,
title = "Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer",
abstract = "BACKGROUND: We aimed to evaluate the clinical relevance of p53 and p73 isoforms that modulate the function of p53.METHODS: This prospective multicentre study included 154 patients with stage III and IV serous ovarian cancer. A functional yeast-based assay and subsequent sequencing were performed to analyse the p53 mutational status. Expression of p53 and p73 isoforms was determined using RT-qPCR.RESULTS: Δ133p53 expression constituted an independent prognostic marker for recurrence-free (hazard ratio=0.571, P=0.016, 95% CI: 0.362-0.899) and overall survival (hazard ratio=0.365, P=0.004, 95% CI: 0.182-0.731) in patients with p53 mutant ovarian cancer (n=121). High Δ40p53 expression was associated with favourable tumour grading (P=0.037) and improved recurrence-free survival (33.4 vs 19.6 months, P=0.029), but not overall survival (43.1 vs 33.6 months, P=0.139), in patients with p53 wild-type cancer (n=33). Neither the p53 mutational status nor p73 isoform expression possessed prognostic significance in the examined ovarian cancer cases.CONCLUSION: Δ133p53 expression was associated with prognosis in the vast majority of ovarian cancer cases, that is, patients with p53 mutant advanced serous carcinomas. Thus, our findings underline the importance of considering the complex p53 regulatory network.",
keywords = "Adult, Aged, Aged, 80 and over, Female, Genes, p53, Humans, Middle Aged, Mutation, Ovarian Neoplasms, Prognosis, Prospective Studies, Real-Time Polymerase Chain Reaction, Tumor Markers, Biological, Tumor Suppressor Protein p53",
author = "G Hofstetter and A Berger and E Schuster and A Wolf and G Hager and I Vergote and I Cadron and J Sehouli and Braicu, {E I} and S Mahner and P Speiser and C Marth and Zeimet, {A G} and H Ulmer and R Zeillinger and N Concin",
note = "2011 Cancer Research UK",
year = "2011",
month = nov,
day = "8",
doi = "10.1038/bjc.2011.433",
language = "English",
volume = "105",
pages = "1593--9",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "10",

}

RIS

TY - JOUR

T1 - Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer

AU - Hofstetter, G

AU - Berger, A

AU - Schuster, E

AU - Wolf, A

AU - Hager, G

AU - Vergote, I

AU - Cadron, I

AU - Sehouli, J

AU - Braicu, E I

AU - Mahner, S

AU - Speiser, P

AU - Marth, C

AU - Zeimet, A G

AU - Ulmer, H

AU - Zeillinger, R

AU - Concin, N

N1 - 2011 Cancer Research UK

PY - 2011/11/8

Y1 - 2011/11/8

N2 - BACKGROUND: We aimed to evaluate the clinical relevance of p53 and p73 isoforms that modulate the function of p53.METHODS: This prospective multicentre study included 154 patients with stage III and IV serous ovarian cancer. A functional yeast-based assay and subsequent sequencing were performed to analyse the p53 mutational status. Expression of p53 and p73 isoforms was determined using RT-qPCR.RESULTS: Δ133p53 expression constituted an independent prognostic marker for recurrence-free (hazard ratio=0.571, P=0.016, 95% CI: 0.362-0.899) and overall survival (hazard ratio=0.365, P=0.004, 95% CI: 0.182-0.731) in patients with p53 mutant ovarian cancer (n=121). High Δ40p53 expression was associated with favourable tumour grading (P=0.037) and improved recurrence-free survival (33.4 vs 19.6 months, P=0.029), but not overall survival (43.1 vs 33.6 months, P=0.139), in patients with p53 wild-type cancer (n=33). Neither the p53 mutational status nor p73 isoform expression possessed prognostic significance in the examined ovarian cancer cases.CONCLUSION: Δ133p53 expression was associated with prognosis in the vast majority of ovarian cancer cases, that is, patients with p53 mutant advanced serous carcinomas. Thus, our findings underline the importance of considering the complex p53 regulatory network.

AB - BACKGROUND: We aimed to evaluate the clinical relevance of p53 and p73 isoforms that modulate the function of p53.METHODS: This prospective multicentre study included 154 patients with stage III and IV serous ovarian cancer. A functional yeast-based assay and subsequent sequencing were performed to analyse the p53 mutational status. Expression of p53 and p73 isoforms was determined using RT-qPCR.RESULTS: Δ133p53 expression constituted an independent prognostic marker for recurrence-free (hazard ratio=0.571, P=0.016, 95% CI: 0.362-0.899) and overall survival (hazard ratio=0.365, P=0.004, 95% CI: 0.182-0.731) in patients with p53 mutant ovarian cancer (n=121). High Δ40p53 expression was associated with favourable tumour grading (P=0.037) and improved recurrence-free survival (33.4 vs 19.6 months, P=0.029), but not overall survival (43.1 vs 33.6 months, P=0.139), in patients with p53 wild-type cancer (n=33). Neither the p53 mutational status nor p73 isoform expression possessed prognostic significance in the examined ovarian cancer cases.CONCLUSION: Δ133p53 expression was associated with prognosis in the vast majority of ovarian cancer cases, that is, patients with p53 mutant advanced serous carcinomas. Thus, our findings underline the importance of considering the complex p53 regulatory network.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Female

KW - Genes, p53

KW - Humans

KW - Middle Aged

KW - Mutation

KW - Ovarian Neoplasms

KW - Prognosis

KW - Prospective Studies

KW - Real-Time Polymerase Chain Reaction

KW - Tumor Markers, Biological

KW - Tumor Suppressor Protein p53

U2 - 10.1038/bjc.2011.433

DO - 10.1038/bjc.2011.433

M3 - SCORING: Journal article

C2 - 22009029

VL - 105

SP - 1593

EP - 1599

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 10

ER -